Validation Data Gallery
Tested Applications
| Positive WB detected in | HEK-293 cells, A549 cells, HeLa cells |
| Positive IP detected in | HEK-293 cells |
| Positive IHC detected in | human lymphoma tissue, mouse spleen tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF/ICC detected in | HepG2 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:1000 |
| Immunoprecipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
| Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| KD/KO | See 3 publications below |
| WB | See 9 publications below |
| IHC | See 4 publications below |
| IF | See 1 publications below |
| IP | See 3 publications below |
| CoIP | See 2 publications below |
| ChIP | See 1 publications below |
Product Information
23959-1-AP targets BCL3 in WB, IHC, IF/ICC, IP, CoIP, chIP, ELISA applications and shows reactivity with human, mouse samples.
| Tested Reactivity | human, mouse |
| Cited Reactivity | human, mouse |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag21040 Product name: Recombinant human BCL3 protein Source: e coli.-derived, PET30a Tag: 6*His Domain: 97-446 aa of BC064993 Sequence: NLPTPLYPMMCPMEHPLSADIAMATRADEDGDTPLHIAVVQGNLPAVHRLVNLFQQGGRELDIYNNLRQTPLHLAVITTLPSVVRLLVTAGASPMALDRHGQTAAHLACEHRSPTCLRALLDSAAPGTLDLEARNYDGLTALHVAVNTECQETVQLLLERGADIDAVDIKSGRSPLIHAVENNSLSMVQLLLQHGANVNAQMYSGSSALHSASGRGLLPLVRTLVRSGADSSLKNCHNDTPLMVARSRRVIDILRGKATRPASTSQPDPSPDRSANTSPESSSRLSSNGLLSASPSSSPSQSPPRDPPGFPMAPPNFFLPSPSPPAFLPFAGVLRGPGRPVPPSPAPGGS 相同性解析による交差性が予測される生物種 |
| Full Name | B-cell CLL/lymphoma 3 |
| Calculated molecular weight | 446 aa, 47 kDa |
| Observed molecular weight | 48-60 kDa |
| GenBank accession number | BC064993 |
| Gene Symbol | BCL3 |
| Gene ID (NCBI) | 602 |
| RRID | AB_2879375 |
| Conjugate | Unconjugated |
| Form | |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | P20749 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol{{ptg:BufferTemp}}7.3 |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
BCL3 (B-cell lymphoma 3 protein) has seven ankyrin repeat domains, a proline-rich N terminal domain and a serine- and proline-rich C-terminal domain(PMID: 31930327). BCL3 is an important contributor to chronic inflammatory disease states, such as osteoarthritis and rheumatoid arthritis (PMID: 12483727). BCL3 is a predominantly nuclear protein containing a trans-activation domain, and it can be recruited to NF-κB-responsive promoters, resulting in transcriptional activation or repression depending on the subunit composition of NF-κB complexes (PMID: 25089799, PMID: 30135206). BCL3 is known to be overexpressed in human breast cancers and is associated with reduced metastasis-free survival (PMID: 38255248).
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for BCL3 antibody 23959-1-AP | Download protocol |
| IHC protocol for BCL3 antibody 23959-1-AP | Download protocol |
| IP protocol for BCL3 antibody 23959-1-AP | Download protocol |
| WB protocol for BCL3 antibody 23959-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Nucleic Acids Res SPaRTAN, a computational framework for linking cell-surface receptors to transcriptional regulators. | ||
Carcinogenesis Bcl-3 promotes multi-modal tumour cell migration via NF-κB1 mediated regulation of Cdc42.
| ||
J Biol Chem The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells.
| ||
Int J Oncol BCL‑3 promotes cyclooxygenase‑2/prostaglandin E2 signalling in colorectal cancer. |
